Glucotrack Sets 1-for-2 Reverse Split to Hold Nasdaq Listing
GCTK is trading near its 52-week low of $0.59 (9.7% above the low).
Summary
Glucotrack will execute a 1-for-2 reverse stock split, the step it flagged in the October 14 preliminary proxy as necessary to keep its Nasdaq listing. The move comes after a 1-for-15 reverse split on August 31, 2026, meaning shareholders face a second consolidation in under two months. The company is under going-concern doubt with a cash crisis disclosed in the Q2 10-Q, and it has stacked dilutive financings — a $5.5M PIPE and bridge in August and $11.6M of convertible notes with a 22% OID in September. A reverse split does not fix the underlying cash burn; it only buys time on the $1 bid-price requirement. Watch whether the split is enough to satisfy Nasdaq's minimum bid threshold and whether further dilution follows through the approved $50M equity line.
At the time of this announcement, GCTK was trading at $0.65 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.5M. The 52-week trading range was $0.59 to $112.50. This news item was assessed with negative market sentiment and an importance score of 7 out of 10. Source: Seeking Alpha.